Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide

Maurizio Averna, Jeanine Roeters Van Lennep, Rodrigo Alonso

    Risultato della ricerca: Articlepeer review

    32 Citazioni (Scopus)

    Abstract

    Homozygous familial hypercholesterolaemia (HoFH) is a rare genetic disease characterised by markedly elevated plasma levels of low-density lipoprotein-cholesterol (LDL-C). Lomitapide is a microsomal triglyceride transfer protein (MTP) inhibitor approved as an adjunct to other lipid-lowering therapies (LLTs), with or without lipoprotein apheresis (LA), for the treatment of adult HoFH. Diet with
    Lingua originaleEnglish
    pagine (da-a)607-617
    Numero di pagine11
    RivistaJOURNAL OF CLINICAL LIPIDOLOGY
    Volume9
    Stato di pubblicazionePublished - 2015

    All Science Journal Classification (ASJC) codes

    • ???subjectarea.asjc.2700.2724???
    • ???subjectarea.asjc.2700.2705???
    • ???subjectarea.asjc.2900.2916???
    • ???subjectarea.asjc.2700.2712???

    Fingerprint

    Entra nei temi di ricerca di 'Treating homozygous familial hypercholesterolemia in a real-world setting: Experiences with lomitapide'. Insieme formano una fingerprint unica.

    Cita questo